INVESTORS

We welcome you to Sofwave’s Investor Relations page and would like to thank you for your interest in our company. Through this page you can find comprehensive and detailed information about our company and the performance of Sofwave.

The information on this page website is especially tailored for institutional investors, analysts and private shareholders as well as anyone interested in Sofwave’s performance.

To our partners and stakeholders,

The Sofwave family is appalled by the unconscionable actions that have transpired in Israel in recent days. We stand in solidarity with the victims of these horrific terrorist acts, and we express our deepest condolences, thoughts and prayers to those impacted.

We are focused on the well-being of our Israeli employees, providing them with the support required. While events in Israel are evolving, our global activity and the supply of our products are expected to continue as planned. We are monitoring the situation closely and will provide updates if and when needed.

We thank all of our partners and stakeholders that have reached out to express their support and best wishes and are grateful for their continued confidence in Sofwave.

Louis Scafuri
CEO, Sofwave Medical

Sofwave, Strong, Israel

Presentations

Investor Meeting November 2023
Video: Investor Meeting November 2023

Sofwave Medical reports financial results for the third quarter of fiscal year 2023, for the period ended September 30, 2023, and recent business highlights. During the First nine months, we have reached a revenue of $35.0M, +60% year-over-year growth with a gross margin of 73.8%, and pulse recurring revenue of $3.1M, +99% year-over-year growth with over 185,000 treatments performed worldwide. We are also happy to report that we have obtained FDA clearance for treating acne scars, the “Precise” SUPERB™ applicator, and Sofwave Smart™ IoT Module.

Investor Meeting August 2023
Video: Investor Meeting August 2023

Sofwave Medical Reports Second Quarter and First Half 2023 Financial results with continued growth in revenue and narrow in operating loss. Second quarter revenue of $12.4M, +53% year-over-year growth. First-half revenue of $22.8M, +67% year-over-year growth. Operating loss significantly narrows in both the second quarter and first half periods and moves closer to reaching operating break-even.

Investor Meeting May 2023
Video: Invesrtor meeting May 2023

Sofwave Medical reports first quarter fiscal 2023 financial results and recent business highlights. First quarter revenue of $10.4M, +86% Year-Over-Year Growth with over 125,000 treatments performed since initial approval; Global market conditions remain favorable, and demand continues to grow in the noninvasive skin treatments sector, with recurring revenues up 74%, to $2.2M. To learn more, please watch the video.

Q4 and Full Year 2022 Morning’s Earnings Call
Video: Q4 and Full Year 2022 Earnings Call

Sofwave™ Medical LTD reports financial results for the period of fourth quarter and full year 2022 with accelerated growth in revenues and gross margin. Q4 record revenues of $13.8M; 55% year-over-year growth and full year 2022 revenue of $35.6M, a year-over-year increase of 63%. To learn more, please watch the video.

1H 2022 Earning Call
Video: Sofwave's 1H 2022 Earning Call

Sofwave™ Medical LTD reports financial results for the period of January – June 2022 (H1/2022) with accelerated growth in revenues and gross margin. The first half of 2022 revenues reached $13.7 million, an increase of 34% YoY growth, and $2.9 million in recurring revenue from our pulse sales, representing 202% YoY growth. This increase was primarily attributed to the continued marketing and sales investments in the Company’s primary markets and increased demand for the Company’s solutions. To learn more, please watch the video.

Goldberg Webinar
Video: Sofwave™ Investor Webinar with Dr. Goldberg

This exclusive webinar brings together our Sofwave™ management and investors with Dr. David Goldberg to discuss our unique technology, FDA indications, practice ROI and compares our proprietary SUPERB™ technology with existing treatments in the market.

Please note that the following webinar is in both Hebrew and English.

Sofwave Company Profile

Commitment & Passion

Commitment & Passion

Driven by experience and passion, Sofwave Medical is a fast-growing medical aesthetic technology innovator committed to developing cutting-edge technologies for the global aesthetic market.

Game-Changing Approach

Game-Changing Approach

Sofwave Medical’s breakthrough technology brings a new standard of care to aesthetic treatments, providing physicians with smart yet simple, effective and safe aesthetic treatments for their patients.

Heritage of Innovation

Heritage of Innovation

From key founders of the aesthetic industry, Sofwave Medical brings a novel approach to non-invasive skin treatments using proprietary Synchronous Ultrasound Parallel Beam Technology SUPERB™.

Sofwave TM Medical Completes Initial Public Offering on the Tel Aviv Stock Exchange
Video: Sofwave™ Mode of Action

Press Releases

March 6, 2024
Sofwave Medical Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
Read the full article
February 12, 2024
Sofwave Medical Appoints Medical Aesthetics Industry Expert James Bartholomeusz to the Role of Chief Innovation Officer
Read the full article
January 3, 2024
Sofwave Medical Receives 510(k) Marketing Clearance For Pure Impact™ Strength and Muscle Toning Body Module Utilizing PlyoPulse™ EMS Technology
Read the full article
December 24, 2023
Annual General Shareholders Meeting of Sofwave Medical Ltd.
Read the full article
November 08, 2023
Sofwave Medical Reports Third Quarter 2023 Financial Results and Business Highlights
Read the full article
August 30, 2023
Sofwave Medical Announces FDA Clearance of SUPERB™ Technology For Treatment of Acne Scars
Read the full article
August 9, 2023
Sofwave™ Investor Earnings Call Aug 2023 Presentation
Read the full article
August 9, 2023
Sofwave Medical Reports Second Quarter and First Half 2023 Financial Results and Recent Business Highlights
Read the full article
July 27, 2023
Sofwave™ Joins Other Leading Israeli Companies in the Initiative for Women's Equal Rights
Read the full article
May 10, 2023
Sofwave Medical Reports First Quarter Fiscal 2023 Financial Results and Recent Business Highlights
Read the full article
March 30, 2023
Sofwave™ Wins 2023 NewBeauty Award For Best Non-Invasive Cellulite Treatment
Read the full article
March 23, 2023
Sofwave™ Granted FDA Clearance For Latest Innovation: The “Precise” SUPERB™ Applicator
Read the full article
March 8, 2023
Sofwave Medical Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
Read the full article
January 22, 2023
Sofwave Gains Market Approval For Its SUPERB™ Technology in Mexico
Read the full article
December 21, 2022
Sofwave Market Approvals For SUPERB™ Non-Invasive Wrinkle Reduction Technology Now Extends to Taiwan
Read the full article
December 19, 2022
Sofwave Medical Announces FDA Clearance of SUPERB™ Technology For Cellulite
Read the full article
November 8, 2022
Sofwave Medical Reports Third Quarter 2022 Financial Results and Business Highlights
Read the full article
November 6, 2022
Sofwave Gains Pre-Market Approval For SUPERB™ Non-Invasive Wrinkle Reduction Technology in Brazil
Read the full article
October 19, 2022
Sofwave™ Granted U.S. Patent Covering Key Elements of the Company’s Proprietary SUPERB™ Non-Surgical Skin and Collagen Remodeling Technology
Read the full article
August 17, 2022
Sofwave Medical Reports First Half (Hebrew)
Read the full article
August 17, 2022
Sofwave Medical Reports First Half Financial Results and Business Highlights
Read the full article
August 9, 2022
Key Collaboration and Distribution Agreement Signed With Major Partner To Advance Sofwave™ Sales In China’s Growing $29 Billion Aesthetic Medicine Market
Read the full article
May 25, 2022
The medical aesthetic company provides voluntary data for the first quarter of 2022
Read the full article
May 17, 2022
Sofwave™ Technology Wins Major Beauty Awards – 2022 Adding To The 2021 Elle Award
Read the full article
Apr 26, 2022
SOFWAVE™ Is This Year’s NewBeauty Award Winner!
Read the full article
March 10, 2022
Sofwave Medical LTD reports financial results for the full year 2021 with accelerated growth in revenues and gross margin
Read the full article
December 12, 2021
Sofwave™ Awarded ELLE Magazine’s 2021 Future of Beauty Awards!
Read the full article
November 16, 2021
Sofwave™ Announces FDA clearance of New Lifting Indications for Eyebrow, Sub-Mental (beneath the chin) and Neck Facial Areas
Read the full article
September 9, 2021
Sofwave Medical Appoints Assaf Korner as Chief Financial Officer
Read the full article
September 5, 2021
Dr. Glynis Ablon Announces Top Trending Fine Lines and Wrinkle Reduction Treatment Now Offered at Ablon Skin Institute
Read the full article
September 5, 2021
Dr. Glynis Ablon Announces Top Trending Fine Lines and Wrinkle Reduction Treatment Now Offered at Ablon Skin Institute
Read the full article
August 30, 2021
Approval to Market Sofwave™ in South Korea
Read the full article
June 30, 2021
Sofwave™ Medical Raises $50M and Completes Initial Public Offering on the Tel Aviv Stock Exchange
Read the full article
April 20, 2021
Sofwave Receives Australian Regulatory Approval to Market SUPERB™, the Breakthrough Ultrasound Technology Treating Fine Lines & Wrinkles
Read the full article
March 2, 2021
Game-Changing Wrinkle Reduction Device Receives Key Regulatory Clearance in Canada
Read the full article

Stock Exchange Updates

Date

Apr 15, 2024

TASE Number

1175439

Symbol : SOFW

SOFW : TASE

Last
1900 (0.01 NIS)
Change
-1.09%
Volume
2,744
Turnover
52,126 NIS
Open
1921
High
1921
Low
1887
Market Cap.
659,353 NIS Thousands

Last Update: 2024-04-15 13:23:18

Management

Dr. Shimon EckhouseRead More
Dr. Shimon Eckhouse
Chairman & Co-Founder
Louis ScafuriRead More
Louis Scafuri
CEO
Assaf KorenRead More
Assaf Korner
CFO
Genady NahshonRead More
Genady Nahshon
COO & Site Manager
Dr Ruthi AmirRead More
Dr. Ruthie Amir
Chief Medical Officer
Lina OmariRead More
Lina Omari
Chief Digital Officer
Ariel SverdlikRead More
Ariel Sverdlik
Co-Founder and CTO
James BartholomeuszRead More
James Bartholomeusz
Chief Innovation Officer

Public Reports 2022

Wage Difference Report

According to section 6b(b) to the Male and Female Employees Equal Pay Law-1996

Download

    Contact Us

    Fill out the form below and we will reach out to you.

    © 2023 Sofwave TM